The manuscript by Osorio et al describes Isthmin as a new negative inhibitor of Nodal. Using chick embryonic assays, gene expression markers for left-right asymmetry, combined with HEK cell culture based co-immunoprecipitaions, the authors show that Ism1 inhibits Nodal-dependent Phopho-Smad2 levels. This inhibition is mediated extracellularly, through direct association of ISM to both Nodal and the ACVR1 receptor, but not to the co-receptor. The authors also show that ISM1 is glycosylated, and this is essential for its inhibitory activity. NODAL inhibition by ISM is not as pronounced as LEFTY inhibitors.
Overall the m/s reports an interesting, new secreted inhibitor of Nodal. The experiments are by and large logical and the data largely supports the authors claims. However a key piece of evidence is missing and their model of Nodal pathway needs to be amended.
Major comments: * The authors suggest that ISM1 only associates with ACVR1B and claim that it does not interact with ACVR2B. However, their data does not rule out an interaction of ISM with ACVR2A. The ACVR2A and 2B receptors can have distinct activities-e.g., the BMP inhibitor Myostatin binds to ACVR2B more efficiently than ACVR2A. Whether ISM interacts with ACVR2A is an essential piece of evidence -this needs to be tested. * I am puzzled by the model in Fig 9 where the authors show that NODAL binds the Type1 receptor ACVR1B. A large body of work on TGF-beta related proteins has shown that the ligands typically bind to the Type 2 receptor, which then recruits the Type1 receptor to trigger Smad phosphorylation and signalling.
Why do the authors think NODAL binds to the type 1 (ACVR1B) and not Type 2 receptor ? There is, in fact, in vivo binding affinity data (Wang et al., 2016) reporting NODAL binding to ACVR2A. Unless the authors can conclusively show that NODAL binds directly to ACVR1 (and Not to ACVR2), their model in Figure 9 should be amended. * Vg1/GDF1 forms heterodimers with NODAL in both mammalian cells and in zebrafish. This is consistent with the authors finding that ISM inhibits both NODAL and GDF1-dependent Smad2 phosphorylation. These papers should be cited.
Minor comments: Some figures are awkwardly oriented/hard to read and should be rearranged (e.g., Fig 5D) .
There are numerous syntax and grammatical errors throughout the m/s, and it would benefit immensely from being proof-read by a native speaker of the English language.
Reviewer #3 (Comments to the Authors (Required)):
Summary: This paper presents an exciting set of findings implicating ISM1 as a secreted inhibitor of Nodal signaling and providing substantive illumination regarding its mechanism of action. The authors use a combination of cell-based assays and chick embryological assays to show (1) that secreted murine ISM1 has two N-glycosylation sites that are critical for secretion, (2) that ISM1 specifically inhibits the extent to which Nodal signaling can induce (A) Smad2 phosphorylation in cells, (B) Smad2/Foxh1-dependant luciferase transcription in cells and (C) ectopic NODAL transcription in chick embryos. A comparison with other Nodal inhibitors suggests that ISM1 is a stronger inhibitor than CER1, but weaker than LEFTY1. They go on to demonstrate in co-IP studies that ISM1 specifically binds both to NODAL and to the extracellular domain of the NODAL receptor ACVR1B, that this binding requires ISM1's AMOP domain, and that ISM1 specifically diminishes the extent to which NODAL and ACVR1B bind each other. Finally, in chick embryological assays, the authors show that ectopic ISM1 diminishes expression of the Nodal-signaling target genes NODAL and CER1, but, curiously, not LEFTY1.
Overall this is a thorough study with novel findings that serves to advance the field, the figures are for the most part clear and of high quality and the rationale for each experiment is very well presented.
Major Criticism. 1. In Fig 5B, the same cells are shown twice, once with the DAPI channel only and then once with the DAPI + red channel. Once this problem is fixed with the correct panel, it would also be useful to provide a bar chart of puncta counts, as was done for Fig. 7D . 2. I see a caveat to the entire exercise in Fig. 4 of comparing the inhibitory activities of ISM1, CER1 and LEFTY1. The problem is that the relative quantities of each protein in the conditioned media are unknown (at least to the reader) and it is therefore not clear if the different readouts are due to different specific activities or different molarities. I think the authors could improve the paper by addressing this matter through further explanation of the experimental design or with additional data, such as molar estimates based on IPs of the CMs.
Minor Criticisms. 1. The hypothesized role for ISM1 in chick asymmetry is interesting, but the authors only superficially reference their 2014 findings on ISM1 expression, citing evidence of asymmetric ISM1 expression without saying where or when in development this asymmetry is observed. As far as I could quickly ascertain, the text of that 2014 paper makes no mention of asymmetric expression, although it seems that the figures may indeed show asymmetric expression. This current paper would be much more interesting if the authors would more precisely discuss how their current experimental data and their previous expression data TOGETHER point to a role for ISM1 in asymmetry. 2. The introduction reads long, and in my opinion undertakes an overly comprehensive review of TGFbeta signaling and an overly detailed preview of their experimental findings. I recommend the introduction focus more on the key players of this study: ISM1 and Nodal signaling. The authors also might consider updating their background information to include the emerging evidence that NODAL signaling is effected via NODAL/GDF3 heterodimers, rather than via NODAL homodimers (PMID 29140250 & PMID 29140251) 3. In Fig. 6C , ACVR3BECD-MYC is included in most lanes, but it is not mentioned in the text, and the rationale for including it is not clear to me. 4. The finding in Fig. 8 that LEFTY1 expression is unaltered by ISM1 CM treatment of chick embryos seems inconsistent with the other findings. It would be good to say a few words in the results or discussion section about why that might be. 5. The authors' hypothesis that the lack of secretion of non-N-glycosylated ISM1 is due to degradation in the ER seems to be contradicted by its abundance in the whole cell lysates of Fig.  1C . If this critique is valid, the authors should revise or clarify that discussion point. 6. This is perhaps more a complaint to JCB than to the authors, but I hate reviewing manuscripts with no page numbers! Reviewer #4 (Comments to the Authors (Required)):
The manuscript entitled 'ISM1 inhibits NODAL signalling by compromising NODAL-ACVR1 interaction' by Osorio et al establishes ISM1 as a new regulator of the NODAL signaling pathway. The authors show that ISM1 binds both NODAL and ACVR1B and prevents the formation of NODAL -ACVR1B complexes, thus inhibiting signaling. The authors use a number of different assays, such as co-IP, reporter assays, and in situ hybridization to establish the molecular and biological significance of the ISM1-NODAL -ACVR1B interaction. Overall, they potentially identify a novel regulator of TGF-beta family signaling. Their results may hint at a role for the elusive AMOP domain found in MUC4 and other secreted proteins of biomedical significance.
The experiments generally appear of good quality and evidence for the interactions is acceptable.
Specific comments on the text:
• A major problem of this manuscript is that it suffers from a significant number of grammatical, wording, and punctuation errors. In addition, articles are missing or misplaced throughout the manuscript. The writing must be corrected. Install proofreading software such as Grammarly or have the article copy-edited to improve the quality of the writing. It is essential that the authors revisit the language of the manuscript.
• The introduction reads like an extensive review. It should be focused on the topic at hand. The introduction could and should be shorted.
• Also, there are many errors of intellectual laxity. An example is the title. The authors have ACVR1 in the title, but the molecule actually tested is ACVR1B. These two receptors have completely different functions. Please, correct.
• Another example is the interchangeable use of Cripto and CFC1. These are different genes with different functions. The alternate name for CFC1 is Cryptic. The authors must correct this oversight and ascertain that the Cripto and Cryptic genes were not mixed up in their studies. Based on the description of the His-CFC1 construction, it is likely that the authors worked with the Cripto gene. This needs to be confirmed.
• In the introduction, the statement 'about 40 members have been identified in the mammalian genome' is simply not good enough for this level of publication. Check the exact number and correct the value in the manuscript to provide an accurate representation of the number of TGF-beta ligands in the mammalian genome.
• In the figure legends, the authors state that they use nanogram quantities of recombinant growth factors. In the methods, they state that they use microgram quantities. Which one is it? This needs to be clarified.
• Can the authors state the following sentence more clearly: 'In addition, ISM1 effect requires the presence of the AMOP domain but is independent of the TSR1 domain'. Can the authors also reconcile their finding that the TSR1 domain, which they originally hypothesized to be critical for regulation of TGF-beta family signaling, is not? Specific comments to the experiments:
• In figures 2 and 4, the authors use Western blot quantification to show statistical significance. To get a better idea of the Western blot reproducibility It would be very helpful if the authors provided two or three examples of their repeat samples in a supplemental figure. Phospho-Smad western blots are notoriously problematic and having this additional information would increase confidence in the results.
• The manuscript is overly reliant on pull-downs of overexpressed proteins to identify interactions. These types of experiments can be prone to artifacts. It is therefore strongly recommended that the authors demonstrate using one alternative approach that NODAL and ACVR1B actually interact with ISM1. Native gel electrophoresis, cross-linking, ITC, SPR, or BLI come to mind as excellent, alternative approaches that would help validate the interaction.
• In Figure 5A . Why does Flag Nodal show in the -Nodal/+ISM1 Lane and not in the +Nodal/-ISM1 lane? Why is the opposite true for ISM1? Can the authors ascertain that they did not make the same mistake in their pull-down and mix up lanes? Due to the uncertainty of the result, it may be recommended that the authors repeat the experiment. Clearly a significant oversight.
• Figure 5A . The authors should ascertain that Flag-tagged Nodal makes bioactive, disulfide-linked homodimers by running reducing and non-reducing gels with their flag Nodal CM.
• Can the authors clarify where the Flag tag was introduced in LEFTY1? Is the position of the Flag tag consistent with biological activity? Tagging these molecules while maintaining biological activity is not trivial. Too many manuscripts in this field have relied on random tagging that results in inactive materials without the authors realizing (or ignoring) the problem.
• Can the authors specify what the boundaries of the ΔAMOP and ΔTSR1 constructs are? Can the authors explain how Inhibition of NODAL signaling by ISM1 requires the AMOP domain and glycosylation (Fig 2D/E, 3A) . Yet, based on the UniProt definition, the AMOP domain does not have a glycosylation site? A better explanation is necessary.
• Figure 6A is frankly not believable. How can the authors make the protein in HEK293 cells, treat the conditioned medium with ENDOH and obtain the same deglycosylation as with PNGASE? This result as described in the manuscript is not possible. The result in itself is disturbing because it raises questions about the validity of other data. This type of oversight is not acceptable. The comparable result in Figure 1A is more believable. Please clarify.
• Right to left reading of figure 6 is confusing and unnecessary. A more standard left to right orientation would be suggested.
• The following statement from the discussion 'Despite this, the ligand-dependent effect of ISM1 in signalling by TGFβ superfamily members seems dependent on CFC1' is extremely speculative and is not supported by direct data. The authors only show that ISM1 inhibits Nodal but not Activin A and take that to mean that CFC1 is critical for this effect. The authors should revise their thinking and not draw such wide-ranging conclusions that could introduce significant confusion to the field, unless they can provide direct evidence demonstrating the dependence of ISM1 inhibition on CFC1/Cripto.
• The following statement is very strong and not warranted by the data from figure 4. 'We found that each of these molecules antagonizes the signalling pathway at different extents and, accordingly to our results, the highest level of inhibition is achieved by LEFTY1, followed by ISM1 and then CER1. These differences in the magnitude of NODAL inhibition by its three antagonists is likely to reflect the mechanism underlying their effect. CER1 uses a single mechanism whereas both LEFTY and ISM1 use a dual but distinct mechanism.' This statement and the corresponding results section are highly speculative, as the authors use CM of CER1, LEFTY1 and ISM to draw quantitative conclusions. Cells were transfected with different amounts of DNA to generate the CM. The authors assume that this leads to linear and equivalent increases in the produced inhibitors. But there is no indication or knowledge of the amount of active, secreted CER1, LEFTY1 or ISM1. The comparisons are therefore weak at best. Nevertheless, their study offers qualitative evidence for the activity of ISM1. The authors should be aware of the limitations of their approach and consider those limitations. The above statement should therefore be reconsidered in light of the qualitative nature of the experiment and focus on the strengths of the observation, rather than the weak, pseudo-quantitative result.
Response: Thanks for the information and we have included several papers (Tanaka et al., 2007; Furer et al., 2014; Montagne and Schier, 2017.) in the introduction and discussion sections in the revised manuscript.
Minor comments:
4/ Some figures are awkwardly oriented/hard to read and should be rearranged (e.g., Fig  5D) .
Response:
We apologize for the inconvenience caused and we have revised and rearranged Fig. 5 and Fig. 6 to make them easy to read.
5/ There are numerous syntax and grammatical errors throughout the m/s, and it would benefit immensely from being proof-read by a native speaker of the English language.
Response: We apologize for the errors and mistakes throughout the manuscript. We have now revised the entire manuscript carefully and have the manuscript edited through the professional service to correct the syntax and grammatical errors. 
Reviewer #3
Major Criticism: Fig 5B, Fig. 7D .
1/ In

Response:
We apologize for the mistake made during the rush preparation of the figures. We have now replaced the figure with correct one in the revised manuscript (Fig. 5B) . In addition, we have included statistical analyses on both the average number of the puncta (PLA) per cell and percentage of Puncta (PLA)-positive cells, in Fig.5B and Fig.7D in the revised manuscript. Fig. 4 
2/ I see a caveat to the entire exercise in
of comparing the inhibitory activities of ISM1, CER1 and LEFTY1. The problem is that the relative quantities of each protein in the conditioned media are unknown (at least to the reader) and it is therefore not clear if the different readouts are due to different specific activities or different molarities. I think the authors could improve the paper by addressing this matter through further explanation of the experimental design or with additional data, such as molar estimates based on IPs of the CMs.
Response: We agree that the previous data provided in Fig. 4 were not able to allow a direct comparison of the inhibitory effects among ISM1, LEFTY1 and CER1. To circumvent this problem, we have modified the experimental design. We cloned the cDNA of ISM1, LEFTY1 and CER1 into a FLAG-tagged mammalian expression vector to express each of these constructs in HEK293T cells for conditioned medium (CM) collection. The relative protein levels (in molarities) of ISM1, LEFTY1 and CER1 representing their relative concentrations in the CM were analysed and determined by Western blotting using FLAG antibodies. Since all three proteins contain FLAG-tag, their relative concentrations in CM can be determined and compared (in molarities). CM with comparable concentrations of ISM, LEFTY1 and CER1 were used to treat HEK293T-CRIPTO cells in the presence of NODAL. The pSMAD2 levels and dual luciferase reporter activities in HEK293T-CRIPTO cells treated by different CM were analysed and compared to determine the relative inhibitory strength of ISM1, LEFTY1 and CER1.
In the revised manuscript, we have revised the data of Figure 4 as described experiment above. Our data showed that LEFTY1 is the most potent inhibitor of NODAL signalling whereas ISM1 exhibited a considerable weaker activity than LEFTY1, but similar or slightly higher inhibitory potential compared with CER1 (Fig.4) Response: We apologize for the lack of detailed description of ISM1 distribution. Asymmetric distribution of ISM1 mRNA in Chick embryos (HH10) was observed in the foregut endoderm of HH10 chick embryos (Osório et al., 2014) . Asymmetric distribution of Ism1 mRNA is also observed in the anterior mesendoderm of E7.5 mouse embryos (Figure below, left panel, Osorio et al. Cell Cycle. 2014) . The asymmetrical expression of Ism1 is also clearly observed in regions adjacent to the node at E7.75 revealed by whole mount in situ hybridization (see Figure below, right panel, unpublished data) . We have added this information to the revised manuscript.
4/ The introduction reads long, and in my opinion undertakes an overly comprehensive review of TGFbeta signaling and an overly detailed preview of their experimental findings. I recommend the introduction focus more on the key players of this study: ISM1 and Nodal signaling. The authors also might consider updating their background information to include the emerging evidence that NODAL signaling is effected via NODAL/GDF3 heterodimers, rather than via NODAL homodimers (PMID 29140250 & PMID 29140251).
Response: Thanks for the suggestion! We have now amended the introduction focusing on ISM1 and NODAL signaling accordingly. Detailed preview of the experimental findings has been removed. Introduction has also been updated so that literature on NODAL/GDF1 and NODAL/GDF3 heterodimers as required for NODAL signalling are included (Levine et al., 2009; Peterson et al., 2013; Pellicia et al., 2017) . 
5/ In Fig. 6C, ACVR3BECD-MYC is included in most lanes, but it is not mentioned in the text, and the rationale for including it is not clear to me.
12/ Can the authors clarify where the Flag tag was introduced in LEFTY1? Is the position of the Flag tag consistent with biological activity? Tagging these molecules while maintaining biological activity is not trivial. Too many manuscripts in this field have relied on random tagging that results in inactive materials without the authors realizing (or ignoring) the problem.
Response: The plasmid pcDNA3-FLAG-LEFTY1 has been described previously (Chen and Shen, 2004) . The epitope tag was inserted after the second proprotein convertase cleavage site. We do agree with the reviewer that tagging molecules while keeping their biological activity is not trivial. However, we do show in Figure 4 that expression of this construct leads to decrease both in the levels of phosphorylated SMAD2 and in the transcriptional activity of SMAD2/FOXH1. This shows that FLAG-LEFTY is indeed biologically active. (Fig 2D/E, 3A) .
13/ Can the authors specify what the boundaries of the ΔAMOP and ΔTSR1 constructs are? Can the authors explain how Inhibition of NODAL signaling by ISM1 requires the AMOP domain and glycosylation
Yet, based on the UniProt definition, the AMOP domain does not have a glycosylation site? A better explanation is necessary.
Response: To clarify the sites of glycosylation and the boundaries of ΔAMOP and ΔTSR1 constructs, we have included a diagram in revised manuscript (Fig. 6A) . The boundaries for TSR1 and AMOP domains have been previously described (Osorio et al., 2014) : TSR1 domain spans amino acids 215-259 and AMOP domain spans amino acids 286-449. ISM1 protein is glycosylated at residues N39 and N282. N39 is located in the N-terminus, 10 amino acids downstream the signal peptide (amino acids 1-29) and N282 is located in the region between TSR1 and AMOP domains (amino acids 260-285). Our data is consistent with the UniProt definition referenced by the reviewer and shows that the AMOP domain does not contain any N-glycosylate site. The inhibition of NODAL-induced SMAD2 activation depends on the presence of functional ISM1 in the CM. N-glycosylation of ISM1 protein is essential for its secretion: eliminating N-glycosylation dramatically reduced the amount of ISM1 in the CM. The deletion of AMOP domain does not affect the N-glycosylation of ISM1. However, AMOP domain is required for the binding of ISM1 to NODAL ligand and ACVR1B. Therefore, deletion of AMOP jeopardize the inhibitory activity of ISM1 to NODAL signalling (Fig 6E) . Figure 6A is Figure 1A is more believable. Please clarify.
14/
Response: I think the reviewer may have mistakenly interpreted the data. The original Fig.  6A showed Western blot of ISM1 in WCL samples (but not CM samples) of HEK293T cells transiently transfected with ISM1, ΔTSR1 and ΔAMOP and digested with PNGase F or Endo H. This was clearly indicated in the figure (see image below) as well as in its legend. To avoid confusion, we now include both WCL samples and CM samples in the revised Figure (revised Fig. 6B ). The results are consistent with Fig. 1A .
Original Figure 6A Revised Figure 6B When looking carefully to the images, one can see that there is a difference in the migration of the bands treated with PNGase F or Endo H. This result is indeed comparable with that of Fig.1A . It supports the finding that intracellular ISM1 proteins, full length as well as domaindeleted forms, all contain predominantly oligomannose N-glycans as well as a few complex types of N-glycans (that are more prominent in the secreted forms). Thank you for submitting your revised manuscript entitled "ISM1 inhibits NODAL signalling by compromising NODAL-ACVR1 interaction". The manuscript has been seen by the original reviewers whose full comments are appended below. While the reviewers continue to be overall positive about the work in terms of its suitability for JCB, some important issues remain.
The remaining comments about two of the figures raised by the Reviewer #3 (point #2 and #3) require somewhat substantive changes to the figures and text and this should be addressed for resubmission. The grammatical mistakes described by Reviewer #3 (point #1) can be corrected in copy editing during production, so further editing of the english is not necessary at this stage. Please also attend to the following formatting requests:
-alternative title suggestion to make the advance accessible to as broad an audience as possible: "ISM1 regulates NODAL signaling and asymmetric organ morphogenesis during development" -Suggested edits to the abstract for clarity and to make the main findings clearer to as broad an audience as possible: "Isthmin 1 (ISM1) was originally identified as a fibroblast group factor expressed in Xenopus embryonic brain but its biological functions remain unclear. The spatiotemporal distribution of ISM1 with high expression in the anterior primitive streak of the chick embryo, and the anterior mesendoderm of the mouse embryo, suggested that ISM1 may regulate signaling by the NODAL subfamily of TGBbeta cytokines that control embryo patterning. We report that ISM1 is an inhibitor of NODAL signaling. ISM1 has little effect on TGFβ1, ACTIVIN-A or BMP4 signaling but specifically inhibits NODAL-induced phosphorylation of SMAD2. In line with this observation, ectopic ISM1 causes defective left-right asymmetry and abnormal heart positioning in chick embryos. Mechanistically, ISM1 interacts with NODAL ligand and type I receptor ACVR1B through its AMOP domain, which compromises the NODAL-ACVR1B interaction and down-regulates phosphorylation of SMAD2. Therefore, we identify ISM1 as an extracellular antagonist of NODAL and reveal a negative regulatory mechanism that provides greater plasticity for the fine-tuning of NODAL signaling." -Please provide main and supplementary figures as separate, editable files according to the instructions for authors on JCB's website, paying particular attention to the guidelines for preparing images and blots at sufficient resolution for screening and production -Format references for JCB -Add scale bars to Fig 5B and 7D -Provide tables as excel files Our general policy is that papers are considered through only one revision cycle; however, given that the suggested changes are relatively minor we are open to one additional short round of revision. Please note that I will expect to make a final decision without additional reviewer input upon resubmission.
Please submit the final revision within one month, along with a cover letter that includes a point by point response to the remaining reviewer comments.
Thank you for this interesting contribution to Journal of Cell Biology. You can contact me or the scientific editor listed below at the journal office with any questions, cellbio@rockefeller.edu or call (212) 
Journal of Cell Biology ---------------------------------------------------------------------------
Reviewer #2 (Comments to the Authors (Required)):
The revised m/s has addressed the major concerns.
My points have been addressed, and the quality of the paper is substantially improved. But I see three easy ways that further improvements could be made. 1) Despite having used a professional editor, the english is full of little mistakes. Most are related to missing or misplaced articles (the/a/an). Use of "which" when "that" should be used is another issue. Finally, there is a use of "secretary" rather than "secretory." So further editing would help.
2) In line with my previous criticism of comparisons made between activities of conditioned media where there was no quantification/normalization of the input protein, I believe the final three of the six bars shown in Fig. 2E and final three of the six bars shown in Fig. 3A lack scientific value. It is established in Fig. 1 that the N39Q and N284Q mutations disrupt secretion, so the comparison of CM activities associated with these mutations and CM activities of WT Isthmin makes no sense to me. Indeed, the CM Westerns shown in Fig 2D demonstrate that the maximum quantity (associated with N284Q) is on the order of 25% that of the WT Isthmin and the other mutants are MUCH lower than even that. So, comparing these mutants' activities with that of Isthmin and concluding that this is due to the mutation rather than due to the precipitous decrease in concentration that is shown makes no sense to me. I strongly recommend removing the data for these mutant CMs from Fig 2D and 3A and the associated discussion in the text. 3) The experiments in figure 7 suggest that Cripto can bind to either Nodal or ACVR1B in the presence of high Isthmin. It seems to me there is an opportunity to revise Fig. 9 to reflect this apparent lack of steric inhibition. This could be done by modifying the righthand panel to show both Nodal and Nodal-Isthmin complexes binding to Cripto and also to show Isthmin-Acvr1B/Cripto association.
